Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16 Genitourinary 10 Head & Neck 5 Gastrointestinal 5 Thoracic 4 Plasma cell 4 Other 4 Lymphoid 4 Gynecologic 3 Dermatologic 3 Other hematologic neoplasm 2 Tumor-Agnostic 1 Sarcoma 1 Other solid neoplasm 1 Other neoplasm 1 Myeloid 1 Classical hematology 1 CNS 1

Conditions

Interventions

Radiotherapy 215 Cyclophosphamide 210 Doxorubicin 207 Temozolomide 181 Ifosfamide 121 Filgrastim 111 Etoposide 101 Imatinib Mesylate 99 Vincristine 92 Gemcitabine 89 Bevacizumab 83 Irinotecan 79 Magnetic Resonance Spectroscopy 78 pembrolizumab 75 Radiation 66 Carboplatin 65 pazopanib 60 Methotrexate 60 Nivolumab 58 Cisplatin 58 fludarabine phosphate 56 Peripheral Blood Stem Cell Transplantation 56 Specimen Handling 53 Docetaxel 50 Busulfan 48 Trabectedin 47 Biopsy 47 Melphalan 46 Surgical Procedures, Operative 44 Paclitaxel 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sugars × Sarcoma × Clear all

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡